Stock listing
Stuttgart:NPAU BetterLife Pharma Inc. Aktie
German listing (Stuttgart) of BetterLife Pharma Inc. · home listing CSE:BETR
Follow BetterLife Pharma Inc. into a list and get an email when it puts out news.
Home listing price · CSE:BETR
$0.185 CAD -0.020 (-9.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, CSE:BETR
- Day range
- $0.185 – $0.200 CADNov 20, 2026
- Volume
- 105,700 sharesNov 20, 2026
- Market cap
- $120.5M CADAt the close on Nov 20, 2026 · price × 651.3M shares outstanding
- 52-week range
- $0.040 – $0.460 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $116,452 CADMedian day 256,309 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:BETR · Home | $0.185 CAD | -0.020 (-9.8%) | 105,700 | $0.190 | $0.200 | $0.185 | $0.205 | Close on Nov 20, 2026 |
| OTC:BETRF | $0.139 USD | -0.002 (-1.3%) | 2,500 | $0.133 | $0.139 | $0.133 | $0.141 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · CSE:BETR · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.185 | -0.020 | -9.8% | $0.190 | $0.200 | $0.185 | 105,700 | |
| $0.205 | -0.005 | -2.4% | $0.185 | $0.220 | $0.180 | 219,507 | |
| $0.210 | +0.010 | +5.0% | $0.215 | $0.225 | $0.200 | 609,125 | |
| $0.200 | 0.000 | 0.0% | $0.200 | $0.220 | $0.185 | 107,000 | |
| $0.200 | -0.015 | -7.0% | $0.200 | $0.200 | $0.200 | 550 | |
| $0.215 | +0.010 | +4.9% | $0.200 | $0.215 | $0.200 | 31,620 | |
| $0.205 | +0.015 | +7.9% | $0.195 | $0.205 | $0.195 | 268,500 | |
| $0.190 | -0.015 | -7.3% | $0.200 | $0.215 | $0.180 | 2,098,071 | |
| $0.205 | -0.020 | -8.9% | $0.220 | $0.225 | $0.205 | 161,500 | |
| $0.225 | +0.005 | +2.3% | $0.230 | $0.230 | $0.210 | 341,300 | |
| $0.220 | -0.010 | -4.3% | $0.220 | $0.220 | $0.215 | 118,666 | |
| $0.230 | +0.005 | +2.2% | $0.225 | $0.230 | $0.215 | 128,554 | |
| $0.225 | -0.015 | -6.2% | $0.240 | $0.240 | $0.220 | 622,500 | |
| $0.240 | -0.010 | -4.0% | $0.250 | $0.250 | $0.240 | 142,106 | |
| $0.250 | 0.000 | 0.0% | $0.260 | $0.260 | $0.245 | 750,847 | |
| $0.250 | +0.010 | +4.2% | $0.245 | $0.260 | $0.245 | 144,000 | |
| $0.240 | +0.015 | +6.7% | $0.235 | $0.250 | $0.235 | 116,021 | |
| $0.225 | 0.000 | 0.0% | $0.230 | $0.230 | $0.220 | 16,600 | |
| $0.225 | 0.000 | 0.0% | $0.230 | $0.235 | $0.225 | 248,100 | |
| $0.225 | -0.020 | -8.2% | $0.240 | $0.240 | $0.225 | 345,435 | |
| $0.245 | -0.005 | -2.0% | $0.250 | $0.260 | $0.230 | 501,610 | |
| $0.250 | +0.050 | +25.0% | $0.210 | $0.285 | $0.210 | 2,032,641 | |
| $0.200 | -0.010 | -4.8% | $0.210 | $0.215 | $0.200 | 144,800 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.225 | $0.210 | 116,326 | |
| $0.210 | -0.015 | -6.7% | $0.230 | $0.230 | $0.210 | 467,301 | |
| $0.225 | +0.005 | +2.3% | $0.225 | $0.230 | $0.220 | 132,057 | |
| $0.220 | -0.025 | -10.2% | $0.250 | $0.250 | $0.220 | 456,300 | |
| $0.245 | -0.010 | -3.9% | $0.260 | $0.260 | $0.245 | 300,607 | |
| $0.255 | -0.015 | -5.6% | $0.280 | $0.280 | $0.255 | 314,343 | |
| $0.270 | +0.010 | +3.8% | $0.260 | $0.270 | $0.250 | 311,500 | |
| $0.260 | -0.005 | -1.9% | $0.260 | $0.270 | $0.260 | 129,967 | |
| $0.265 | -0.025 | -8.6% | $0.295 | $0.295 | $0.265 | 269,089 | |
| $0.290 | +0.025 | +9.4% | $0.290 | $0.290 | $0.270 | 30,701 | |
| $0.265 | -0.005 | -1.9% | $0.270 | $0.285 | $0.265 | 372,951 | |
| $0.270 | -0.075 | -21.7% | $0.315 | $0.320 | $0.270 | 921,958 | |
| $0.345 | +0.060 | +21.1% | $0.300 | $0.345 | $0.290 | 73,010 | |
| $0.285 | -0.025 | -8.1% | $0.315 | $0.315 | $0.285 | 283,489 | |
| $0.310 | -0.025 | -7.5% | $0.330 | $0.330 | $0.305 | 319,050 | |
| $0.335 | -0.015 | -4.3% | $0.350 | $0.355 | $0.330 | 198,701 | |
| $0.350 | +0.015 | +4.5% | $0.335 | $0.350 | $0.335 | 184,428 | |
| $0.335 | +0.015 | +4.7% | $0.335 | $0.345 | $0.330 | 181,700 | |
| $0.320 | +0.015 | +4.9% | $0.320 | $0.330 | $0.305 | 209,113 | |
| $0.305 | -0.025 | -7.6% | $0.335 | $0.350 | $0.300 | 1,535,561 | |
| $0.330 | -0.030 | -8.3% | $0.355 | $0.360 | $0.330 | 248,618 | |
| $0.360 | 0.000 | 0.0% | $0.350 | $0.390 | $0.340 | 861,522 | |
| $0.360 | -0.020 | -5.3% | $0.390 | $0.390 | $0.350 | 505,800 | |
| $0.380 | -0.020 | -5.0% | $0.400 | $0.400 | $0.360 | 392,698 | |
| $0.400 | +0.060 | +17.6% | $0.340 | $0.400 | $0.340 | 1,124,392 | |
| $0.340 | +0.035 | +11.5% | $0.315 | $0.340 | $0.315 | 184,786 | |
| $0.305 | +0.005 | +1.7% | $0.300 | $0.310 | $0.300 | 264,000 | |
| $0.300 | -0.005 | -1.6% | $0.305 | $0.305 | $0.300 | 44,015 | |
| $0.305 | +0.005 | +1.7% | $0.305 | $0.305 | $0.300 | 31,533 | |
| $0.300 | 0.000 | 0.0% | $0.305 | $0.305 | $0.300 | 615,167 | |
| $0.300 | +0.015 | +5.3% | $0.285 | $0.310 | $0.280 | 892,540 | |
| $0.285 | -0.005 | -1.7% | $0.295 | $0.295 | $0.280 | 195,000 | |
| $0.290 | 0.000 | 0.0% | $0.310 | $0.310 | $0.280 | 116,316 | |
| $0.290 | -0.025 | -7.9% | $0.325 | $0.325 | $0.290 | 854,369 | |
| $0.315 | +0.005 | +1.6% | $0.345 | $0.345 | $0.290 | 590,644 | |
| $0.310 | -0.060 | -16.2% | $0.350 | $0.355 | $0.300 | 2,554,040 | |
| $0.370 | -0.010 | -2.6% | $0.375 | $0.380 | $0.350 | 39,195 | |
| $0.380 | +0.060 | +18.8% | $0.320 | $0.380 | $0.300 | 441,701 | |
| $0.320 | -0.005 | -1.5% | $0.320 | $0.320 | $0.295 | 238,893 | |
| $0.325 | +0.010 | +3.2% | $0.320 | $0.330 | $0.300 | 266,880 | |
| $0.315 | -0.035 | -10.0% | $0.315 | $0.340 | $0.310 | 169,019 |
- Ticker
- Stuttgart:NPAU
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
BetterLife Pharma Engages Market Maker
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 18 slides
Latest news
BetterLife Pharma Engages Market Maker
Nov 20, 2026
Closed $0.185 (-9.8%) on Nov 20, 2026
BetterLife Pharma Announces New Preclinical Research Highlighting Neuroplasticity-Related Effects of Non-Hallucinogenic BETR-001 at Neuroscience 2026
Nov 17, 2026
Closed $0.21 (+5.0%) on Nov 17, 2026
BetterLife Pharma Announces Stock Option Grant
Nov 17, 2026
Closed $0.21 (+5.0%) on Nov 17, 2026
BetterLife Pharma Announces Settlement of Claim with Dr. Steven Sangha
Nov 6, 2026
Closed $0.225 (+2.3%) on Nov 6, 2026
2026-11-05 BETR – Board Changes FINAL
Nov 5, 2026
Closed $0.22 (-4.3%) on Nov 5, 2026
BetterLife Pharma Appoints Henry Chow, CPA, CA, to Board of Directors
Nov 5, 2026
Closed $0.22 (-4.3%) on Nov 5, 2026
BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm
Oct 27, 2026
Closed $0.225 (0.0%) on Oct 27, 2026
BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board
Oct 19, 2026
Closed $0.21 (0.0%) on Oct 19, 2026
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations
Oct 15, 2026
Closed $0.225 (+2.3%) on Oct 15, 2026
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
Oct 14, 2026
Closed $0.22 (-10.2%) on Oct 14, 2026
BetterLife Pharma Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 30 in the last 12 months · 86 in all · newest Nov 20, 2026 · oldest 2017
- Decks
- 5 decks · latest July 2026
Where BetterLife Pharma Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:BETR · Home listing | CSE | Canada | CAD |
| OTC:BETRF | OTC | United States | USD |
| Cboe Canada:BETR | Cboe Canada | Canada | CAD |
| Frankfurt:NPAU | Frankfurt | Germany | EUR |
| LS Exchange:A2P7XN | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2P7XN | Lang & Schwarz | Germany | EUR |
| gettex:NPAU | gettex | Germany | EUR |
| Stuttgart:NPAU · This page | Stuttgart | Germany | EUR |
| Munich:NPAU | Munich | Germany | EUR |
Valuation
Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026
- Enterprise value
- $119.6M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P/TSX Composite
- 1.14
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BetterLife Pharma Inc. · CSE:BETR | US$84.02M | US$83.36M | n/a | n/a | n/a | n/a | n/a | n/a | 1.14 |
| Bioceltix SA · GPW:BCX | US$86.39M | US$72.44M | n/a | n/a | n/a | 5.6× | n/a | 0.0× | n/a |
| Perspective Therapeutics, Inc. · AMEX:CATX | US$86.05M | −US$114.1M | n/a | −570× | n/a | 0.3× | n/a | 0.0× | 1.47 |
| Pharmosa Biopharm Inc. · TPEX:6875 | US$86.02M | US$62.26M | n/a | 38.5× | n/a | 2.1× | −658.1% | 0.1× | n/a |
| Formosa Pharmaceuticals, Inc. · TWSE:6838 | US$85.42M | US$48.51M | n/a | 30.4× | n/a | 2.0× | −361.4% | 0.0× | n/a |
| Anixa Biosciences, Inc. · NASDAQ:ANIX | US$84.82M | US$70.96M | n/a | n/a | n/a | 5.9× | n/a | 0.0× | 1.45 |
| Genome & Co. · KRX:314130 | US$84.75M | US$36.98M | n/a | 2.0× | n/a | 1.6× | −169.1% | 0.0× | n/a |
| Shine-On Biomedical Co., Ltd. · TPEX:6926 | US$83.54M | US$59.01M | n/a | 64.8× | n/a | 3.5× | −367.6% | 0.0× | n/a |
| Rallybio Corporation · NASDAQ:RLYB | US$83.29M | −US$7.40M | 3.1× | −17.1× | n/a | 0.9× | n/a | 0.0× | 0.58 |
| TuHURA Biosciences, Inc. · NASDAQ:HURA | US$82.20M | US$89.50M | n/a | n/a | n/a | 4.3× | n/a | 0.5× | 2.81 |
| 3D Medicines, Inc. · HKEX:1244 | US$81.88M | US$48.38M | n/a | 0.9× | n/a | 1.0× | −49.9% | 0.3× | n/a |
| Median of the others | US$84.79M | US$53.76M | 3.1× | 2.0× | 2.1× | −361.4% | 0.0× | 1.46 |
Team and board
Officers
| Officer | Role |
|---|---|
| Ahmad Doroudian | Chief Executive Officer & Director |
| Douglas Drysdale | Executive Chairman |
| Mahan Chehrenama | Chief Medical Officer |
| Sheila Leitzinger | Head of Clinical Operations |
Board
| Director | Role |
|---|---|
| Douglas Drysdale | Executive Chairman |
| Ahmad Doroudian | Chief Executive Officer & Director |
| Charles Duncan | Director |
| Henry Chow | Member of the Board of Directors |
| John W. LaRocca | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 30, 2023 · After close | −11.1% |
| Q3 2023 | Dec 22, 2022 · After close | +6.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 18 slides | July 2026 |
| Investor Presentation (January 2023) | Investor deck | 15 slides | Jan 13, 2023 |
| Investor Presentation (August 2022) | Investor deck | 15 slides | August 2022 |
| Investor Presentation (December 2021) | Investor deck | 23 slides | December 2021 |
| Investor Presentation (May 2021) | Investor deck | 27 slides | May 26, 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Public offering of common shares and pre-funded warrants Closed: US$100M raised · C$0.25 a share · Bloom Burton Securities Inc. +1 Dealers: Bloom Burton Securities Inc. (lead), Haywood Securities Inc. Buyers: Deep Track Capital (led the financing); Coastlands Capital (significant co-investment); Marshall Wace (significant co-investment); RA Capital Management (significant co-investment); Perceptive Advisors (significant co-investment); Adage Capital Management (participation); Affinity Asset Advisors (participation); Kalehua Capital (participation); Sphera Fund Management (participation); Squadron Capital Management (participation); Stonepine Capital Management (participation); Woodline Partners LP (participation) Use of proceeds: Phase 1A, Phase 1B and Phase 2 clinical trials of BETR-001 in cluster headache and migraine, plus working capital and general corporate purposes | Sep 17, 2026 | |
| Convertible debenture Closed: C$2M raised · C$0.06 · 1 warrant at C$0.1 for 36 months Insiders: A director and insider of the Company subscribed for $2,000,000 of the Debenture; conversion subject to a 19.9% ownership cap absent shareholder approval Use of proceeds: Complete remaining IND-enabling activities for BETR-001 and general working capital | Jun 22, 2026 | US$1.41M |
| Warrant exercise of common shares on exercise of share purchase warrants Closed: C$25,000 raised | May 6, 2025 | US$18,138 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Research and development | 85.7K | 424.3K | 570.9K | 2.68M | 5.42M | 284.7K | 63.8K | 364.8K | 86.7K | |
| Selling, general and administrative | 1.72M | 4.30M | 2.64M | 6.56M | 4.53M | 7.56M | 7.74M | 5.13M | 1.04M | |
| Operating income | -1.81M | -5.00M | -3.24M | -9.46M | -9.97M | -7.95M | -9.20M | -6.46M | -1.16M | |
| Depreciation and amortization | 0 | 0 | 18.4K | 18.4K | 18.4K | 2.92K | 1.14K | 30.8K | 30.8K | |
| EBITDA | -5.00M | -3.24M | -9.44M | -9.95M | -7.94M | -9.20M | -6.46M | -1.13M | ||
| Interest expense | 231.9K | 165.1K | 45.5K | 11.5K | 51.8K | 7.05K | 48.0K | 4.86K | 0 | 0 |
| Income before tax | -1.51M | -3.62M | -2.90M | -9.37M | -12.0M | -36.4M | -19.6M | -9.15M | -149.5K | |
| Income tax | 166.7K | |||||||||
| Net income | -1.50M | -3.62M | -2.90M | -9.37M | -12.2M | -36.4M | -19.6M | -9.25M | -149.5K | |
| Earnings per share, basic | -0.01 | -0.08 | -0.05 | -0.31 | -0.39 | -0.71 | -0.25 | -0.96 | -0.02 | |
| Earnings per share, diluted | -0.03 | -0.03 | -0.10 | -0.16 | -1.34 | -1.30 | -1.03 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 12.6K | 8.18K | 37.4K | 8.31K | 173.5K | 154.7K | 3.28M | 74.8K | 79.6K | |
| Receivables | 2.86K | 11.6K | 39.5K | 17.2K | 325.0K | 520.1K | 137.4K | 44.5K | 5.12K | |
| Current assets | 219.9K | 225.0K | 324.7K | 74.7K | 1.14M | 1.33M | 3.48M | 217.4K | 183.5K | 129.8K |
| Property, plant and equipment | 18.4K | 36.9K | 542.7K | 5.31K | ||||||
| Total assets | 219.9K | 225.0K | 324.7K | 74.7K | 1.16M | 1.34M | 8.25M | 10.3M | 473.5K | |
| Accounts payable | 3.95M | 4.50M | 4.98M | 5.44M | 3.34M | 4.50M | -2.37K | 637.3K | 267.9K | 996.9K |
| Current liabilities | 6.68M | 7.54M | 7.35M | 7.15M | 4.14M | 5.85M | 960.1K | 5.40M | 527.6K | 1.61M |
| Long-term debt | 27.2K | 49.1K | 49.1K | 0 | 34.6K | 0 | ||||
| Total debt | 99.2K | 80.0K | 74.6K | 0 | ||||||
| Total liabilities | 6.71M | 7.59M | 8.02M | 7.61M | 5.04M | 5.98M | 5.59M | 6.81M | 529.5K | |
| Shareholders' equity | -9.78M | -7.36M | -7.70M | -7.53M | -3.88M | -4.61M | 2.66M | 3.50M | -56.0K | |
| Shares outstanding | 151.9M | 43.5M | 52.8M | 30.1M | 31.3M | 51.4M | 79.5M | 9.69M | 8.24M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -625.5K | -2.02M | -2.47M | -1.50M | -11.2M | -7.16M | -7.88M | -4.71M | -561.5K | -359.4K |
| Capital spending | 0 | 0 | 0 | 0 | 0 | -10.2K | -542.7K | 0 | -542.7K | -542.7K |
| Free cash flow | -625.5K | -2.02M | -2.47M | -1.50M | -11.2M | -7.18M | -8.42M | -4.71M | -488.1K | -902.2K |
| Cash from investing | -71.5K | -1.14M | -844.4K | -844.4K | -844.4K | |||||
| Cash from financing | 629.3K | 1.99M | 2.50M | 1.34M | 11.2M | 4.09M | 12.2M | 5.55M | 457.3K | 379.7K |
| Change in cash | 4.39K | -29.2K | 29.1K | -165.2K | 18.8K | -3.13M | 3.21M | -4.50K | -67.7K | 40.8K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Sep 29, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 22, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Sep 15, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 11, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 24, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 4, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 26, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 25, 2026 | Current report | SEC |
| 20-F · Annual report | Jun 1, 2026 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Apr 13, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Sep 29, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 28, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 27, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 23, 2025 | Current report | SEC |
| 20-F · Annual report | Jun 2, 2025 | Annual report | SEC |
| 6-K · Report of a foreign issuer | May 29, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 6, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 7, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 31, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 9, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 15, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 26, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 29, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 8, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 15, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 27, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 17, 2024 | Current report | SEC |
| 20-F · Annual report | May 30, 2024 | Annual report | SEC |
| 6-K · Report of a foreign issuer | May 14, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 6, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 11, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 4, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 5, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 2, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 29, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 18, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 30, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 29, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 28, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 5, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 13, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 28, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 28, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 9, 2023 | Current report | SEC |
| 20-F/A · Annual report, amended | Jun 6, 2023 | Annual report | SEC |
| 20-F · Annual report | May 31, 2023 | Annual report | SEC |
| 6-K · Report of a foreign issuer | May 10, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 25, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 14, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 8, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 7, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 28, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 18, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 23, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 8, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 8, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 27, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 12, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 29, 2022 | Current report | SEC |
| 20-F · Annual report | Jun 6, 2022 | Annual report | SEC |
| NT 20-F | May 31, 2022 | Explanation request | SEC |
| 6-K · Report of a foreign issuer | Apr 6, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 4, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 20, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 23, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 16, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 15, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 9, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 23, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 20, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 29, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 23, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 21, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 3, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 16, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 28, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 25, 2021 | Current report | SEC |
| 20-F/A · Annual report, amended | Jun 23, 2021 | Annual report | SEC |
| 20-F/A · Annual report, amended | Jun 8, 2021 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Jun 7, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 7, 2021 | Current report | SEC |
| 20-F · Annual report | Jun 1, 2021 | Annual report | SEC |
| 6-K · Report of a foreign issuer | May 28, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 21, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 14, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 5, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 26, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 20, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 1, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 16, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 15, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 8, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 2, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 19, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 30, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 29, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 22, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 8, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 2, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 23, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 20, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 9, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 28, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 9, 2020 | Current report | SEC |
| 6-K/A · Report of a foreign issuer, amended | Aug 17, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 11, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 31, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 29, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 29, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 15, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 9, 2020 | Current report | SEC |
| 20-F/A · Annual report, amended | Jun 5, 2020 | Annual report | SEC |
| 20-F · Annual report | Jun 1, 2020 | Annual report | SEC |
| NT 20-F | Jun 1, 2020 | Explanation request | SEC |
| 6-K · Report of a foreign issuer | May 26, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 13, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 8, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 22, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 6, 2020 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 26, 2019 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 5, 2019 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 3, 2019 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 8, 2019 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 1, 2019 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 6, 2019 | Current report | SEC |
| 10-Q · Quarterly report | Jun 17, 2019 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Jun 17, 2019 | Explanation request | SEC |
| 8-K · Current report | May 21, 2019 | Financing | SEC |
| 10-K · Annual report | May 3, 2019 | Annual report | SEC |
| NT 10-K · Late filing notice | Apr 30, 2019 | Explanation request | SEC |
| DEF 14A · Proxy statement | Feb 19, 2019 | Meeting notice | SEC |
| 8-K · Current report | Feb 4, 2019 | Financing | SEC |
| 8-K · Current report | Dec 19, 2018 | Material contract | SEC |
| 10-Q · Quarterly report | Dec 18, 2018 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Dec 17, 2018 | Explanation request | SEC |
| 8-K · Current report | Nov 6, 2018 | Financing | SEC |
| 8-K · Current report | Sep 18, 2018 | Management or board change | SEC |
| 10-Q · Quarterly report | Sep 14, 2018 | Quarterly report | SEC |
| 10-Q · Quarterly report | Jun 19, 2018 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Jun 15, 2018 | Explanation request | SEC |
| 8-K/A · Current report, amended | May 16, 2018 | Acquisition or disposal | SEC |
| 10-K · Annual report | May 1, 2018 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2018 | Acquisition or disposal | SEC |
| 8-K · Current report | Dec 19, 2017 | Financing | SEC |
| 10-Q · Quarterly report | Dec 15, 2017 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Oct 27, 2017 | Meeting notice | SEC |
| 10-Q · Quarterly report | Sep 15, 2017 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Sep 15, 2017 | Explanation request | SEC |
| 8-K · Current report | Sep 12, 2017 | Material contract | SEC |
| 10-Q · Quarterly report | Jun 13, 2017 | Quarterly report | SEC |
| 10-K · Annual report | Apr 28, 2017 | Annual report | SEC |
| 10-Q · Quarterly report | Dec 9, 2016 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Nov 28, 2016 | Meeting notice | SEC |
| 10-Q · Quarterly report | Sep 12, 2016 | Quarterly report | SEC |
| 10-Q · Quarterly report | Jun 14, 2016 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jun 7, 2016 | Annual report | SEC |
| 10-K · Annual report | Apr 29, 2016 | Annual report | SEC |
| 8-K/A · Current report, amended | Feb 3, 2016 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Dec 15, 2015 | Quarterly report | SEC |
| D | Dec 7, 2015 | Other filings | SEC |
| DEF 14A · Proxy statement | Nov 25, 2015 | Meeting notice | SEC |
| 8-K · Current report | Nov 23, 2015 | Material contract | SEC |
| 8-K · Current report | Nov 18, 2015 | Management or board change | SEC |
| 8-K · Current report | Nov 17, 2015 | Material contract | SEC |
| 10-Q · Quarterly report | Sep 10, 2015 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2015 | Financing | SEC |
| 10-Q · Quarterly report | Jun 17, 2015 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jun 17, 2015 | Annual report | SEC |
| NT 10-Q · Late filing notice | Jun 15, 2015 | Explanation request | SEC |
| 10-K · Annual report | May 15, 2015 | Annual report | SEC |
| NT 10-K · Late filing notice | May 4, 2015 | Explanation request | SEC |
| 8-K · Current report | Apr 17, 2015 | Current report | SEC |
| 8-K · Current report | Mar 26, 2015 | Material contract | SEC |
| 5 · Annual statement of ownership | Mar 10, 2015 | Insider trade | SEC |
| 5 · Annual statement of ownership | Mar 10, 2015 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 10, 2015 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 3, 2015 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 3, 2015 | Insider trade | SEC |
| 8-K · Current report | Feb 10, 2015 | Management or board change | SEC |
| 10-Q · Quarterly report | Dec 15, 2014 | Quarterly report | SEC |
| 8-K · Current report | Oct 9, 2014 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Sep 15, 2014 | Quarterly report | SEC |
| DEFR14A | Aug 27, 2014 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Aug 25, 2014 | Other filings | SEC |
| DEFR14A | Aug 20, 2014 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Aug 15, 2014 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Aug 8, 2014 | Meeting notice | SEC |
| 8-K · Current report | Jul 28, 2014 | Management or board change | SEC |
| 10-Q · Quarterly report | Jun 16, 2014 | Quarterly report | SEC |
| 8-K · Current report | Jun 4, 2014 | Meeting outcome | SEC |
| 10-K · Annual report | May 16, 2014 | Annual report | SEC |
| NT 10-K · Late filing notice | May 2, 2014 | Explanation request | SEC |
| DEF 14A · Proxy statement | Apr 30, 2014 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 10, 2014 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 9, 2014 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 8, 2014 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 1, 2014 | Meeting notice | SEC |
| 8-K · Current report | Mar 18, 2014 | Current report | SEC |
| 10-Q · Quarterly report | Dec 16, 2013 | Quarterly report | SEC |
This page holds 200 of 244 filings. Open Filings
Cap table
Built by 6ix from BetterLife Pharma Inc.’s releases · as of Sep 17, 2026
- Common shares
- 651,340,512
- Fully diluted
- 877,049,527
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 651,340,512 | Jun 22, 2026 |
| Warrants | 212,909,015 | Sep 17, 2026 |
| Options and RSUs | 12,800,000 | Jun 15, 2026 |
Warrants and options
| Lot |
|---|
| Broker warrants · C$0.25 · expire Sep 17, 2029 |
| Warrants · C$0.10 · expire about Jun 2029 |
| Warrants · C$0.10 · expiry not stated |
| Stock options · C$0.07 · expiry not stated |
| Stock options · C$0.25 · expiry not stated |
| Stock options · expiry not stated |
| Stock options · expiry not stated |
| Stock options · expiry not stated |
| Stock options · C$0.29 · expiry not stated |
| Stock options · C$0.19 · expiry not stated |
All 12 lots
| Lot |
|---|
| Stock options · C$0.065 · expire Jun 15, 2036 |
| Stock options · C$0.065 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 651,340,512 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Barbara-Jean Anne Bormann-Kennedy Other companies: BioLineRX Ltd. (Director · Since at least Mar 18, 2026); Xeris Biopharma Holdings, Inc. (Director · Since at least Oct 5, 2021) | President, Director · Feb 5, 2015 – Feb 5, 2015 · Past |
| Moira Ong Other companies: Vansen Pharma Inc (CFO/Secretary · Feb 24, 2014 – Feb 24, 2014 · Past) | Chief Financial Officer · Mar 3, 2015 – Mar 3, 2015 · Past |
| Ahmad Doroudian | Chief Executive Officer & Director · Since at least Mar 10, 2015 |
| Bri Lees | Head of Marketing · Oct 23, 2025 – Nov 4, 2026 · Past |
| Charles Duncan | Director · Since at least Aug 31, 2026 |
| Doug Drysdale | Executive Chairman · Since at least May 13, 2026 |
| Doug Drysdale | Executive Chairman and Director · Since May 13, 2026 · Appointed, no departure found |
| Henry Chow | Member of the Board of Directors · Since at least Nov 5, 2026 |
| John W. LaRocca | Director · Since at least Jul 9, 2026 |
| Mahan Chehrenama | Chief Medical Officer · Since at least Aug 19, 2026 |
All 15 people
| Person | Seat |
|---|---|
| Mark Swaim | Officer · Since May 11, 2020 · Appointed, no departure found |
| Richard B. Lipton | Co-Chair · Oct 19, 2026 – Nov 5, 2026 · Past |
| Sheila Leitzinger | Head of Clinical Operations · Since at least Oct 15, 2026 |
| Steven Sangha | Director · Mar 31, 2025 – Nov 4, 2026 · Past |
| Toni Rinow | Until Jan 22, 2020 · Past |
Log in to ask 6ix AI your own questions about BetterLife Pharma Inc.